The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Recent Update of Radiologic Findings and Interventional Methods of Pancreas Endocrine Tumor

췌장 내분비 종양의 최신 영상의학 소견과 인터벤션 기법

  • Kim, Jing-Woong (Department of Radiology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Jeong, Yong-Yeon (Department of Radiology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School)
  • 김진웅 (전남대학교 의과대학 화순전남대학교병원 영상의학과) ;
  • 정용연 (전남대학교 의과대학 화순전남대학교병원 영상의학과)
  • Published : 2011.04.01
⟨ Previous Next ⟩

Abstract

Pancreatic endocrine tumors (PET) are rare neoplasms of the pancreas accounting for less than 5% of all primary pancreatic malignancies. Insulinomas, gastrinomas, glucagonomas and somatostatinomas is included in PET. PETs are usually classified into functioning and non-functioning tumors and presents with a range of benignity or malignancy. It is very important to accurate diagnose the PET location and to predict the benignity or malignancy of PET in terms of the treatment strategy, because PET have higher respectability, better response to chemotherapy and better prognosis compared to that of pancreatic adenocarcinoma. The utility and reliability of different imaging modalities depends on the characteristics of PETs, specifically their size. Functioning PET tend to be small (less than 2 cm), well circumscribed, homogeneous, and usually shown as strong enhancement on contrast enhanced CT or MR imaging. Non-functioning PET tend to be larger (4~10 cm), heterogeneous, and may contain the cystic areas of degeneration and necrosis. In this article, we present the various imaging findings of PET according to recent WHO classification.

Keywords

References

  1. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas: analysis of autopsy cases. Dig Dis Sci 1991;36:933-942. https://doi.org/10.1007/BF01297144
  2. Frankel WL. Update on pancreatic endocrine tumors. Arch Pathol Lab Med 2006;130:963-966.
  3. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-1733. https://doi.org/10.1093/annonc/mdn351
  4. Solcia EKG, Sobin LH. Histological Typing of Endocrine Tumours (World Health Organization International Classification of Tumours). 2nd ed. Berlin: Springer, 2000.
  5. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Onco 2008;34:324-332. https://doi.org/10.1016/j.ejso.2007.07.209
  6. Galiber AK, Reading CC, Charboneau JW, et al. Localization of pancreatic insulinoma: comparison of pre- and intraoperative US with CT and angiography. Radiology 1988;166:405-408. https://doi.org/10.1148/radiology.166.2.2827232
  7. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271-2277. https://doi.org/10.1111/j.1572-0241.2000.02480.x
  8. Sugiyama M, Abe N, Izumisato Y, et al. Differential diagnosis of benign versus malignant nonfunctioning islet cell tumors of the pancreas: the roles of EUS and ERCP. Gastrointest Endosc 2002;55:115-119. https://doi.org/10.1067/mge.2002.119604
  9. Norton JA, Cromack DT, Shawker TH, et al. Intraoperative ultrasonographic localization of islet cell tumors: a prospective comparison to palpation. Ann Surg 1988;207:160-168. https://doi.org/10.1097/00000658-198802000-00008
  10. Zeiger MA, Shawker TH, Norton JA. Use of intraoperative ultrasonography to localize islet cell tumors. World J Surg 1993;17:448-454. https://doi.org/10.1007/BF01655103
  11. Keogan MT, McDermott VG, Paulson EK, et al. Pancreaticmalignancy: effect of dual-phase helical CT in tumor detection and vascular opacification. Radiology 1997;205:513-518. https://doi.org/10.1148/radiology.205.2.9356637
  12. Schirmer WJ, Melvin WS, Rush RM, et al. Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma. Surgery 1995;118:1105-1113. https://doi.org/10.1016/S0039-6060(05)80121-7
  13. Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000;216:163-171. https://doi.org/10.1148/radiology.216.1.r00jl26163
  14. Noldge G, Weber MA, Ritzel RA, Werner MJ, Kauczor HU, Grenacher L. Invasive diagnostic procedures for insulinomas of the pancreas. Radiologe 2009;49:224-232. https://doi.org/10.1007/s00117-008-1786-7
  15. Baba Y, Miyazono N, Nakajo M, Kanetsuki I, Nishi H, Inoue H. Localization of insulinomas: comparison of conventional arterial stimulation with venous sampling (ASVS) and superselective ASVS. Acta Radio 2000;41:172-177. https://doi.org/10.1080/028418500127345000
  16. Kisker O, Bartsch D, Weinel RJ, et al. The value of somatostatinreceptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 1997;184:487-492.
  17. Weinel RJ, Neuhaus C, Stapp J, et al. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg 1993;218:640-645. https://doi.org/10.1097/00000658-199321850-00009
  18. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998;228:228-238. https://doi.org/10.1097/00000658-199808000-00013
  19. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996;125:26-34. https://doi.org/10.7326/0003-4819-125-1-199607010-00005
  20. Schillaci O, Massa R, Scopinaro F. 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 2000;41:459-462.
  21. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008;49:573-586. https://doi.org/10.2967/jnumed.107.045708
  22. Rha SE, Jung SE, Lee KH, Ku YM, Byun JY, Lee JM. CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 2007;62:371-377. https://doi.org/10.1016/j.ejrad.2007.02.036
  23. Hong YJ, Yu JS, Park C, et al. Islet cell tumors of the pancreas: a variety of multiphaseDynamic imaging findings with pathologic correlations focusing on nonfunctioning tumors and insulinomas. J Korean Soc Radiol 2010;63:463-469. https://doi.org/10.3348/jksr.2010.63.5.463
  24. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005;19:195-211. https://doi.org/10.1016/j.beem.2004.11.013